Literature DB >> 15934268

Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy.

Alan Shrim1, Gideon Koren.   

Abstract

QUESTION: A 27-year-old patient of mine with rheumatoid arthritis has been treated with infliximab for the last 5 years. She is planning her first pregnancy. How should I advise her regarding use of infliximab during pregnancy, bearing in mind that infliximab substantially improved her medical condition? ANSWER: Infliximab (Remicade) has not been tested in pregnant animals because it does not interact with non-human tumour necrosis factor (TNF) alpha. Several case reports describing women who used infliximab during pregnancy do not suggest a strong association with adverse pregnancy outcomes. More studies are required to determine infliximab's safety during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934268      PMCID: PMC1472927     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  4 in total

1.  Infliximab treatment and pregnancy outcome in active Crohn's disease.

Authors:  R Srinivasan
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

2.  Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.

Authors:  Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

Review 3.  Safety of tumour necrosis factor-alpha antagonists.

Authors:  Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.

Authors:  Eliza F Chakravarty; Deanna Sanchez-Yamamoto; Thomas M Bush
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.